NCT01324076Unknown3 期
TACE-2: A Randomized Placebo-Controlled, Double Blinded, Phase III Trial of Sorafenib in Combination With Transarterial Chemoembolization in Hepatocellular Cancer
适应症
相关药物
试验速览
- 阶段
- 3 期
- 入组人数
- 412
- 试验地点
- 8
- 主要终点
- Progression-free survival
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Chemoembolization kills tumor cells by carrying drugs directly into the tumor and blocking the blood flow to the tumor. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. It is not yet known whether transarterial chemoembolization using doxorubicin-eluting beads is more effective when given with or without sorafenib tosylate in treating patients with liver cancer that cannot be removed by surgery.
PURPOSE: This randomized phase III trial is studying giving transarterial chemoembolization using doxorubicin-eluting beads and sorafenib tosylate to see how well it works compared with giving transarterial chemoembolization using doxorubicin-eluting beads and a placebo in treating patients with liver cancer that cannot be removed by surgery.
详细描述
OBJECTIVES:
Primary
- To determine whether the addition of sorafenib tosylate to transarterial chemoembolization (TACE) with doxorubicin-eluting beads, compared to TACE alone, prolongs progression-free survival of patients with unresectable hepatocellular carcinoma.
Secondary
- To determine if adding sorafenib tosylate to TACE prolongs overall survival of these patients.
- To determine if the sorafenib tosylate regimen prolongs time to progression in these patients.
- To determine acceptable toxicity related to the sorafenib tosylate regimen in these patients.
- To determine the effects of the sorafenib tosylate regimen on disease response, in terms of complete response, partial response, or stable disease, in these patients.
- To determine the effects of the sorafenib tosylate regimen on quality of life of these patients.
- To determine if treatment with the sorafenib tosylate regimen reduces the frequency for repeat TACE as measured by number of TACE procedures performed in 12 months.
- To establish a blood sample bank linked to this study for biomarker research (proteomic and genomic analysis).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically or cytologically confirmed hepatocellular carcinoma (HCC) OR meets the American Association for the Study of Liver Diseases (AASLD) criteria for diagnosis of HCC
- •Unresectable disease
- •Not amenable to liver transplantation
- •At least one uni-dimensionally measurable lesion according to the RECIST criteria by CT scan or MRI
- •Child-Pugh A (score ≤ 6) and no Child-Pugh cirrhosis C or B (score ≥ 7)
- •No ascites refractory to diuretic therapy
- •No documented occlusion of the hepatic artery or main portal vein
- •No extrahepatic metastasis or hepatic encephalopathy
- •PATIENT CHARACTERISTICS:
- •ECOG performance status 0-1
- •Life expectancy > 3 months
- •Hemoglobin ≥ 9 g/L
- •Absolute neutrophil count ≥ 1.5 x 10^9/L
- •Platelet count ≥ 60,000/μL
- •Bilirubin ≤ 50 μmol/L
- •Alkaline phosphatase < 4 times upper limit of normal (ULN)
- •AST and ALT < 5 times ULN
- •Creatinine ≤ 1.5 times ULN
- •Amylase and lipase < 2 times ULN
- •INR ≤ 1.5
- •LVEF ≥ 45%
- •Able to swallow oral medication
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception during study and for 3 months after completion of study treatment
- •No history of bleeding within the past 4 weeks
- •No contraindications for hepatic embolization procedures, including portosystemic shunt, hepatofugal blood flow, or known severe atheromatosis
- •No hypersensitivity to intravenous contrast agents
- •No active clinically serious infection > grade 2 (NCI-CTC version 4)
- •No known history of HIV infection
- •No history of second malignancy except non-melanotic skin cancer or cervical carcinoma in situ or malignancy treated with curative intent with > 3 years without relapse
- •No evidence of severe or uncontrolled disease including any of the following:
- •Systemic disease
- •Cardiac arrhythmias (requiring anti-arrhythmic therapy or pacemaker)
- •Hypertension
- •NYHA class III or IV congestive cardiac failure
- •Myocardial infarction within the past 6 months
- •Laboratory finding that, in the view of the Investigator, makes it undesirable for the patient to participate in the trial
- •No psychiatric or other disorder likely to impact on informed consent
- •PRIOR CONCURRENT THERAPY:
- •At least 4 weeks since prior and no concurrent investigational therapy
- •No prior embolization, systemic therapy, or radiotherapy for HCC
- •No major surgery within the past 4 weeks
- •No ablative therapy (radiofrequency ablation or percutaneous ethanol injection) for HCC
- •Patients with untreated target lesion(s) and ablation occurred > 6 weeks prior to study entry allowed
- •No concurrent rifampicin or St. John wort
- •No concurrent bone marrow transplant or stem cell rescue
- •No concurrent bevacizumab or drugs that target VEGF or VEGF receptors
- •No other concurrent anticancer chemotherapy, immunotherapy, hormone therapy, or molecular therapy except bisphosphonates
排除标准
- 未提供
结局指标
主要结局
Progression-free survival
次要结局
- Overall survival
- Time to progression
- Toxicity
- Disease control (complete or partial response or stable disease)
- Quality of life
研究者
研究点 (8)
Loading locations...
相似试验
终止
1 期
Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver CancerLiver CancerNCT01009801Swiss Group for Clinical Cancer Research27
Unknown
3 期
Doxorubicin By Infusion or Chemoembolization in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)Liver CancerNCT00079027University Hospital Birmingham280
终止
1 期
Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity CancerFallopian Tube CancerPrimary Peritoneal Cavity CancerOvarian CancerNCT00303888Yale University31
已完成
2 期
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's LymphomaLymphomaNCT00006125Alliance for Clinical Trials in Oncology
已完成
2 期
Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Stage III Breast CancerBreast CancerNCT00004175Northwestern University